Category: Latest News

The Multiple Sclerosis Association of America (MSAA) is pleased to announce that we are the recipients of three awards from the 26th annual Digital Health Awards®! Organized by the Health Information Resource Center (HIRC), the Digital Health Awards recognize leading digital health resources developed for consumers and health professionals. Award entries are evaluated by type of content, format, targeted consumer audience, and overall quality.

The astounding breadth of research being conducting into the causes, manifestations, and management of multiple sclerosis (MS) was on full display when thousands of physicians, nurses, laboratory scientists, and others gathered in Denver in April for the annual meeting of the American Academy of Neurology (AAN).

The Multiple Sclerosis Association of America (MSAA) and Novartis Pharmaceuticals Corporation have collaborated to develop the Multiple Sclerosis Implementation Network™ (MSIN™). This is an exciting and unique initiative to create a practice-based research network (PBRN) for medical professionals to best support individuals with MS.  MSIN is a patient-centric initiative, emphasizing the vital role of people living with MS and their involvement in this practice-based research network. MSIN will be guided by two advisory boards – one of which will be comprised of people living with MS and their care partners. The other advisory board will be comprised of healthcare professionals, research scientists, and advocacy partners.

The Multiple Sclerosis Association of America (MSAA) is excited to invite members of the MS community to our 10th Improving Lives Benefit on Wednesday, May 15, 2024, at 6:30 pm ET, at the Barnes Foundation in Philadelphia, PA. This event will also be livestreamed, allowing individuals from across the country to participate from the comfort of their homes. Those attending will have the opportunity to connect with inspiring individuals, recognize our special honorees, and support MSAA’s programs and services that are provided at no cost to the MS community.

From February 29th through March 2nd of this year, MS researchers and clinicians gathered in West Palm Beach for the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024. These healthcare professionals came not only to ask questions but also to provide answers obtained from recent studies addressing varied facets of multiple sclerosis.

The Multiple Sclerosis Association of America (MSAA) proudly recognizes March as MS Awareness Month and is pleased to present the 2024 awareness campaign theme of Improving Lives Through Supportive Connections. Throughout the month of March, MSAA will provide various programs focused on the power of social interactions and connections, mental health and emotional support, as well as additional factors that assist in the empowerment and enhancement of the quality of life for individuals affected by multiple sclerosis.

The new year began with welcome news on many fronts in terms of clinicians’ enhanced ability to understand and treat multiple sclerosis (MS) and patients’ enhanced ability to improve their health. This edition of “What’s New in MS Research” highlights several of those findings. They include information on a telehealth program that drove significant weight loss in people contending with both MS and obesity, and an internet-delivered cognitive behavioral therapy intervention designed specifically for people with MS that has been shown to reduce depressive symptoms.

Milan, Italy served as the setting for cutting-edge science and high hopes last month, when multiple sclerosis (MS) researchers and clinicians from around the world gathered there in October for MSMilan2023, the 9th joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS).

This edition of “What’s New in MS Research” opens with a pair of “firsts:” the first listing of multiple sclerosis (MS) therapies on the World Health Organization’s List of Essential Medicines and the first United States Food and Drug Administration (FDA) approval of a biosimilar therapy for the long-term treatment of MS.

The Multiple Sclerosis Association of America (MSAA) is proud to announce that we have received an APEX Award for Excellence from the 35th Annual APEX Awards! This award was presented for MSAA’s Winter/Spring 2022 edition of The Motivator under the Magazines, Journals & Tabloids category for print publications 32 pages and longer.